Strategic Financial Concepts LLC Has $203,000 Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Strategic Financial Concepts LLC trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 99.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 752 shares of the biopharmaceutical company's stock after selling 175,733 shares during the period. Strategic Financial Concepts LLC's holdings in Alnylam Pharmaceuticals were worth $203,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $1,045,822,000. Norges Bank acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth about $577,941,000. Capital Research Global Investors raised its position in shares of Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after acquiring an additional 1,724,610 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after acquiring an additional 1,245,195 shares in the last quarter. Finally, Marshall Wace LLP raised its position in shares of Alnylam Pharmaceuticals by 496.6% in the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock worth $89,100,000 after acquiring an additional 315,182 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. UBS Group boosted their price objective on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. BMO Capital Markets upped their price objective on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research note on Tuesday, June 24th. JPMorgan Chase & Co. raised their price target on Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the stock an "overweight" rating in a report on Thursday, June 12th. Wall Street Zen raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday. Finally, Citigroup increased their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-one have given a buy rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $340.00.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the completion of the sale, the chief executive officer owned 48,948 shares in the company, valued at approximately $14,899,281.72. The trade was a 39.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Stock Up 0.7%

Shares of NASDAQ:ALNY opened at $331.94 on Friday. The stock has a market cap of $43.28 billion, a P/E ratio of -158.82 and a beta of 0.23. The firm has a fifty day moving average price of $294.96 and a 200 day moving average price of $266.07. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $333.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The firm had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. During the same quarter in the previous year, the company posted ($0.16) EPS. The firm's quarterly revenue was up 20.2% compared to the same quarter last year. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.